GlassScriptPhysician profile
Jamison Cullimore Jones
NPI 1205031549
$11,620.40
in general payments reported to CMS, 2019-2025
29 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $1,090 · 2021: $1,309 · 2022: $1,348 · 2023: $3,196 · 2024: $1,447 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,636 · Travel and Lodging: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,635.71 |
| Travel and Lodging | $1,556.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,949.30 | 2021-2025 | Abre, Venaseal, Closurefast |
| Amgen INC. | $1,312.54 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,281.96 | 2019-2025 | |
| Medtronic Vascular, INC. | $857.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $642.91 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $532.87 | 2020-2025 | Varithena Administration Pack, Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $521.03 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Actelion Pharmaceuticals US, INC. | $482.98 | 2019-2025 | Opsumit, Uptravi |
| Pfizer INC. | $425.92 | 2019-2025 | |
| Abbott Laboratories | $368.76 | 2019-2025 | Jot Dx, Cardiomems |
| Tactile Systems Technology INC | $298.08 | 2019-2024 | Flexitouch Plus, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $226.92 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.44 | 2019-2022 | |
| Amarin Pharma, INC. | $91.27 | 2019-2020 | |
| Abiomed | $90.10 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $65.59 | 2021-2023 | Puraply |
| Alnylam Pharmaceuticals INC. | $65.17 | 2021-2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $53.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.82 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.54 | 2019-2023 | Farxiga |
| Merz North America, INC. | $30.76 | 2021-2023 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $29.47 | 2022 | |
| Esperion Therapeutics, INC. | $18.61 | 2021 | |
| Daiichi Sankyo INC. | $17.83 | 2024 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.04 | 2019 | |
| Biotronik INC. | $13.95 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.38 | 2019 | |
| Gilead Sciences, INC. | $12.10 | 2019 | |
| Chiesi USA, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.